

## ■ **ELN Breakfast Meeting and WP meetings at the ASH 2013**

On Sunday December 8<sup>th</sup> the ELN breakfast meeting takes place at the Downtown Marriott. The agenda of this meeting as well as of different work package meetings are now available on the website. ▶ [agenda of the ELN breakfast meeting](#)

## ■ **11th Annual Symposium of the European LeukemiaNet**

The 2014 Annual Symposium of the European LeukemiaNet and the German Competence Network 'Acute and chronic leukemias' is held on February 4 to 5 2013 in Mannheim. The program is now available on the website. ▶ [program of the 11th Annual Symposium of the ELN](#)

## ■ **ELN Flyer 2013**

Recently, the new flyer of the ELN was released. The brochure is available on the website for free download. ▶ [ELN Flyer 2013](#)

## ■ **New molecular insights in emerging therapeutic strategies in Acute Lymphoblastic Leukemia (ALL)**

From February 28 to March 2 2014 the EHA-SWG Scientific Meeting on new molecular insights in emerging therapeutic strategies in Acute Lymphoblastic Leukemia takes place in Lisbon, Portugal. Among the topics covered are genetic alterations and molecular markers, methods and application of MRD, targeted therapies, SCT, and treatment approaches for adolescents and young adults. ▶ [detailed information on this meeting](#)

## ■ **Publications from the Network (selected)**

### **Acute lymphoblastic leukemia**

- ▶ Ben Abdelali R et al. The prognosis of CALM-AF10-positive adult T-cell acute lymphoblastic leukemias depends on the stage of maturation arrest. *Haematologica*. 2013 Nov;98(11):1711-7.
- ▶ Chiaretti S et al. Clinico-biological features of 5202 patients with acute lymphoblastic leukemia enrolled in the Italian AIEOP and GIMEMA protocols and stratified in age cohorts. *Haematologica*. 2013 Nov;98(11):1702-10.
- ▶ Hoelzer D. Targeted therapy with monoclonal antibodies in acute lymphoblastic leukemia. *Curr Opin Oncol*. 2013 Nov;25(6):701-6.
- ▶ Intermesoli T et al. High cure rates in Burkitt lymphoma and leukemia: a Northern Italy Leukemia Group study of the German short intensive rituximab-chemotherapy program. *Haematologica*. 2013 Nov;98(11):1718-25.
- ▶ Lengline E et al. Successful tyrosine kinase inhibitor therapy in a refractory B-cell precursor acute lymphoblastic leukemia with EBF1-PDGFRB fusion. *Haematologica*. 2013 Nov;98(11):e146-8.

### **Acute myeloid leukemia**

- ▶ Freeman SD et al. Prognostic relevance of treatment response measured by flow cytometric residual disease detection in older patients with acute myeloid leukemia. *J Clin Oncol*. 2013 Nov 10;31(32):4123-31.
- ▶ Lo-Coco F et al. Biology and management of therapy-related acute promyelocytic leukemia. *Curr Opin Oncol*. 2013 Nov;25(6):695-700.
- ▶ Müller-Tidow C et al. A randomized, open-label, phase I/II trial to investigate the maximum tolerated dose

of the Polo-like kinase inhibitor BI 2536 in elderly patients with refractory/relapsed acute myeloid leukaemia. *Br J Haematol.* 2013 Oct;163(2):214-22.

- ▶ Nomdedéu JF et al. Bone marrow WT1 levels at diagnosis, post-induction and post-intensification in adult de novo AML. *Leukemia.* 2013 Nov;27(11):2157-64.
- ▶ Sanz MA et al. Acute promyelocytic leukemia: do we have a new front-line standard of treatment? *Curr Oncol Rep.* 2013 Oct;15(5):445-9.
- ▶ Shivarov V et al. DNMT3A mutation is a poor prognosis biomarker in AML: Results of a meta-analysis of 4500 AML patients. *Leuk Res.* 2013 Nov;37(11):1445-50.
- ▶ Terwijn M et al. High Prognostic Impact of Flow Cytometric Minimal Residual Disease Detection in Acute Myeloid Leukemia: Data From the HOVON/SAKK AML 42A Study. *J Clin Oncol.* 2013 Nov 1;31(31):3889-97.

### **Chronic myeloid leukemia**

- ▶ Cortes JE et al. Subcutaneous omacetaxine mepesuccinate in patients with chronic-phase chronic myeloid leukemia previously treated with 2 or more tyrosine kinase inhibitors including imatinib. *Clin Lymphoma Myeloma Leuk.* 2013 Oct;13(5):584-91.
- ▶ Delord M et al. High imatinib dose overcomes insufficient response associated with ABCG2 haplotype in chronic myelogenous leukemia patients. *Oncotarget.* 2013 Oct;4(10):1582-91.
- ▶ Gugliotta G et al. Impact of comorbidities on the treatment of chronic myeloid leukemia with tyrosine-kinase inhibitors. *Expert Rev Hematol.* 2013 Oct;6(5):563-74.
- ▶ Hoffmann VS et al. The EUTOS prognostic score: review and validation in 1288 patients with CML treated frontline with imatinib. *Leukemia.* 2013 Oct;27(10):2016-22.
- ▶ La Rosée P et al. Improved tolerability by a modified intermittent treatment schedule of dasatinib for patients with chronic myeloid leukemia resistant or intolerant to imatinib. *Ann Hematol.* 2013 Oct;92(10):1345-50.
- ▶ Neviani P et al. PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells. *J Clin Invest.* 2013 Oct 1;123(10):4144-57.
- ▶ Nicolini FE et al. The BCR-ABL T315I mutation compromises survival in chronic phase chronic myelogenous leukemia patients resistant to tyrosine kinase inhibitors, in a matched pair analysis. *Haematologica.* 2013 Oct;98(10):1510-6.
- ▶ Thielen N et al. Imatinib discontinuation in chronic phase myeloid leukaemia patients in sustained complete molecular response: a randomised trial of the Dutch-Belgian Cooperative Trial for Haemato-Oncology (HOVON). *Eur J Cancer.* 2013 Oct;49(15):3242-6.

### **Philadelphia-positive leukemias**

- ▶ Cortes JE et al. A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. *N Engl J Med.* 2013 Nov 7;369(19):1783-96.
- ▶ Walker CJ et al. Preclinical and clinical efficacy of XPO1/CRM1 inhibition by the karyopherin inhibitor KPT-330 in Ph+ leukemias. *Blood.* 2013 Oct 24;122(17):3034-44.

### **Chronic lymphocytic leukemia**

- ▶ Hallek M. Signaling the end of chronic lymphocytic leukemia: new frontline treatment strategies. *Blood.* 2013 Nov 28;122(23):3723-34.

### **Myelodysplastic syndromes**

- ▶ Brand R et al. Comparison of allogeneic stem cell transplantation and non-transplant approaches in elderly patients with advanced myelodysplastic syndrome: optimal statistical approaches and a critical appraisal of clinical results using non-randomized data. *PLoS One.* 2013 Oct 7;8(10):e74368.
- ▶ Malcovati L et al. Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet. *Blood.* 2013 Oct 24;122(17):2943-64.
- ▶ Mathis S et al. Flow cytometric detection of dyserythropoiesis: a sensitive and powerful diagnostic tool for

myelodysplastic syndromes. *Leukemia*. 2013 Oct;27(10):1981-7.

- ▶ Schanz J et al. Monosomal karyotype in MDS: explaining the poor prognosis? *Leukemia*. 2013 Oct;27(10):1988-95.

### **Myeloproliferative neoplasms**

- ▶ Barbui T et al. Elevated C-reactive protein is associated with shortened leukemia-free survival in patients with myelofibrosis. *Leukemia*. 2013 Oct;27(10):2084-6.
- ▶ Barbui T et al. Problems and pitfalls regarding WHO-defined diagnosis of early/prefibrotic primary myelofibrosis versus essential thrombocythemia. *Leukemia*. 2013 Oct;27(10):1953-8.
- ▶ Jovanovic JV et al. Establishing optimal quantitative-polymerase chain reaction assays for routine diagnosis and tracking of minimal residual disease in JAK2-V617F-associated myeloproliferative neoplasms: a joint European LeukemiaNet/MPN&MPNr-EuroNet (COST action BM0902) study. *Leukemia*. 2013 Oct;27(10):2032-9.

### **Stem cell transplantation**

- ▶ Fürst D et al. High-resolution HLA matching in hematopoietic stem cell transplantation: a retrospective collaborative analysis. *Blood*. 2013 Oct 31;122(18):3220-9.
- ▶ Gratwohl A et al. Hematopoietic stem cell transplantation activity in Europe. *Curr Opin Hematol*. 2013 Nov;20(6):485-93.
- ▶ Innes AJ et al. Escalating-dose HLA-mismatched DLI is safe for the treatment of leukaemia relapse following alemtuzumab-based myeloablative allo-SCT. *Bone Marrow Transplant*. 2013 Oct;48(10):1324-8.
- ▶ Ringhoffer S et al. T-cell reconstitution after allogeneic stem cell transplantation: assessment by measurement of the sjTREC/ $\beta$ TREC ratio and thymic naive T cells. *Haematologica*. 2013 Oct;98(10):1600-8.
- ▶ Robin M et al. Matched unrelated or matched sibling donors result in comparable outcomes after non-myeloablative HSCT in patients with AML or MDS. *Bone Marrow Transplant*. 2013 Oct;48(10):1296-301.
- ▶ Schmidt-Hieber M et al. CMV serostatus still has an important prognostic impact in de novo acute leukemia patients after allogeneic stem cell transplantation: a report from the Acute Leukemia Working Party of EBMT. *Blood*. 2013 Nov 7;122(19):3359-64.

### **Infectious diseases**

- ▶ Grube M et al. TLR5 stop codon polymorphism is associated with invasive aspergillosis after allogeneic stem cell transplantation. *Med Mycol*. 2013 Nov;51(8):818-25.
- ▶ Öhrmalm L et al. Human parvovirus B19 in pediatric and adult recipients of allogeneic hematopoietic stem cell transplantation. *Bone Marrow Transplant*. 2013 Oct;48(10):1366-7.

### **Miscellaneous**

- ▶ Coorevits P et al. Electronic health records: new opportunities for clinical research. *J Intern Med*. 2013 Dec;274(6):547-60.
- ▶ Dugas M. Time for open access to all medical documentation forms. *BMJ*. 2013 Oct 9;347:f5824.
- ▶ Metzgeroth G et al. Long-term follow-up of treatment with imatinib in eosinophilia-associated myeloid/lymphoid neoplasms with PDGFR rearrangements in blast phase. *Leukemia*. 2013 Nov;27(11):2254-6.

## **■ New trials in the ELTR**

**CLDE225X2116** A Phase Ib/II, Open-label, Multi-center, Dose-finding Study to Assess the Safety and Efficacy of the Oral Combination of LDE225 and INC424 (Ruxolitinib) in Patients With Myelofibrosis

